Therapeutic targeting of HER2-CB₂R heteromers in HER2-positive breast cancer.

ABSTRACT: Although human epidermal growth factor receptor 2 (HER2)-targeted therapies have dramatically improved the clinical outcome of HER2-positive breast cancer patients, innate and acquired resistance remains an important clinical challenge. New therapeutic approaches and diagnostic tools for identification, stratification, and treatment of patients at higher risk of resistance and recurrence are therefore warranted. Here, we unveil a mechanism controlling the oncogenic activity of HER2: heteromerization with the cannabinoid receptor CB₂R. We show that HER2 physically interacts with CB₂R in breast cancer cells, and that the expression of these heteromers correlates with poor patient prognosis. The cannabinoid Δ⁹-tetrahydrocannabinol (THC) disrupts HER2-CB_2<

SUBMITTER: Blasco-Benito S 

PROVIDER: S-EPMC6397550 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature